Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Depression: Depression & Related Conditions
Resources
Basic Information
Introduction and Types of Depressive DisordersRelated Disorders / ConditionsHistorical and Current UnderstandingsBiology, Psychology and SociologyTreatment - Medication and PsychotherapyAlternative Medicine and Self-Help ResourcesSpecial IssuesReferences
More InformationTestsLatest News
Ketamine Nasal Spray Shows Promise Against Depression, SuicideTelltale Clues That Your Child Is DepressedPrenatal Exposure to SSRI Tied to Fetal Brain DevelopmentDepressive Symptoms Tied to Diabetes Self-ManagementAbandoning Your Workouts May Bring on the BluesMany Grad Students Struggle With Anxiety, DepressionRelapse in Major Depression Linked to Brain Cortical ChangesIL-6 Levels Predict Response to ECT in Depressive Disorder1 in 20 Younger Women Suffers Major DepressionHeart-Healthy 'DASH' Diet May Also Help Lower Depression RiskGuidelines Updated for Managing and ID'ing Adolescent Depression21 Reviewed Antidepressants Top Placebo for Major DepressionAntidepressants Do Work, Some Better Than Others: StudyTreatment Initiation for Depression Low in Primary CareDuring 2013 to 2016, 8.1 Percent of U.S. Adults Had DepressionDepression Common in U.S., Women Hit HardestNo Proof At-Home 'Cranial Stimulation' Eases DepressionAcne Linked to Increased Risk of Major Depressive DisorderMany With Depression Delay, Avoid TreatmentPostnatal Depression Tied to Child Behavioral ProblemsTalk Therapy May Be Worth It for Teen DepressionCognitive Behavioral Therapy Cost-Effective in Depressed TeensWomen Seem More Prone to Winter BluesTransdermal Estradiol May Help Prevent Depressive SymptomsHormone Therapy May Ease Depression Linked to MenopauseEsketamine Safe, Effective for Treatment-Resistant DepressionDermatologists Often Undervalue Depression, Anxiety in PatientsFeeling Sad? Here's How to Beat the Holiday BluesImpaired White Matter Integrity for Depression in Parkinson'sHealth Tip: Fight Seasonal Affective DisorderNetwork Density Not Linked to Response in Teen DepressionSimple ECG May Help Distinguish MDD From Bipolar DepressionTreatment Trajectories Vary for Children With DepressionIf Dad Has Depression, Kids Might Develop It, TooPsychedelic Amazonian Drug Might Ease Symptoms of Depression, AlcoholismHelp for Seasonal DepressionOnline CBT Program Beneficial for Depression, AnxietyLocus ID'd That Links Comorbid Alcohol Dependence, DepressionSummer Baby, Higher Odds for Postpartum Depression?More Evidence That Depression Shortens LivesRegular Leisure-Time Exercise May Cut Incidence of DepressionMoving Just 1 Hour a Week May Curb Depression RiskHealth Tip: Do You Need Psychological Therapy?Psychosocial Intervention Ups Adherence to AntidepressantsPostpartum Depression Likely to Recur With Future PregnanciesCancer Patients May Have Undiagnosed DepressionMom-to-Be's Antidepressants Tied to Kids' Psychiatric WoesToo Many New Mothers Silent on Postpartum Depression1 in 5 Moms Mum About Post-Pregnancy BluesGoogle Search for 'Depression' Now to Provide Screening Test
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Bipolar Disorder
Suicide
Addictions: Alcohol and Substance Abuse
Pain Management

21 Reviewed Antidepressants Top Placebo for Major Depression


HealthDay News
Updated: Feb 22nd 2018

new article illustration

THURSDAY, Feb. 22, 2018 (HealthDay News) -- For adults with major depressive disorder, all antidepressants are more efficacious than placebo, according to research published online Feb. 21 in The Lancet.

Andrea Cipriani, M.D., from the University of Oxford in the United Kingdom, and colleagues conducted a systematic review and meta-analysis to compare and rank 21 antidepressants used for the acute treatment of adults with unipolar major depressive disorder. Data were included from 522 trials with 116,477 participants.

The researchers found that all antidepressants were more effective than placebo in terms of efficacy, with odds ratios ranging from 2.13 for amitriptyline to 1.37 for reboxetine. Only agomelatine and fluoxetine correlated with fewer dropouts than placebo in terms of acceptability (odds ratios, 0.84 and 0.88, respectively), while clomipramine was worse than placebo (odds ratio, 1.30). Considering all trials, the between-antidepressant differences in odds ratios varied from 1.15 to 1.55 for efficacy and from 0.64 to 0.83 for acceptability. In head-to-head studies, the most effective antidepressants were agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine, while the least efficacious were fluoxetine, fluvoxamine, reboxetine, and trazodone. Compared with other antidepressants, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable, while the highest dropout rates were seen for amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine.

"These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial